Purpose
|
Linifanib (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively, mostly effective in mutant kinase-dependent cancer cells (i.e. FLT3). Phase 3.
|
Characteristics
|
Target: VEGFR inhibitor Receptor: VEGFR1/FLT1,VEGFR2/KDR, CSF-1R, FLT3,PDGFRβ, Kit,VEGFR3/FLT4
|
Purification
|
All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
|
Purity
|
100?%
|
Formula
|
C21H18FN5O
|
Solubility
|
100 mM in DMSO
|